Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00170755 · ClinicalTrials.gov registry record · Phase 3
A Long-Term Safety, Tolerability and Efficacy Study of Darifenacin in Adult Patients With Overactive Bladder
A Phase 3 study, sponsored by Novartis.
- Completed
- Registry status
- Phase 3
- Development phase
- 718
- Enrollment target
NCT00170755 is a Phase 3 study that has completed, run by Novartis. The registered enrollment target is 718 participants.
The verdict
NCT00170755, a Phase 3 study, has completed, sponsored by Novartis.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 718 participants
- Enrollment target
Study Summary
This study will evaluate the safety, tolerability and efficacy of darifenacin, in the long-term treatment of adult patients with overactive bladder.
Interventions
- DRUG Darifenacin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 718 participants |
| Start Date | 2002-04 |
| Est. Completion | 2005-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00170755
The ClinicalTrials.gov registry entry for NCT00170755 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 718 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis, which has 265 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Darifenacin is the first listed.
NCT00170755 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00170755 about?
NCT00170755 is a clinical study titled "A Long-Term Safety, Tolerability and Efficacy Study of Darifenacin in Adult Patients With Overactive Bladder". This study will evaluate the safety, tolerability and efficacy of darifenacin, in the long-term treatment of adult patients with overactive bladder.
What is the current status of trial NCT00170755?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 718 participants. The study started on 2002-04. Estimated completion is 2005-01.
What interventions are being tested in trial NCT00170755?
The interventions under investigation include: Darifenacin (DRUG).
Who is sponsoring clinical trial NCT00170755?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.